NEW YORK and SCOTTSDALE, Ariz., April 22 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product. Under the agreement, NeoStem will investigate the effects of Homspera(R), ImmuneRegen's lead drug candidate, which has been shown to enhance stem cell activity, in combination with NeoStem's VSEL(TM) technology. Very small embryonic-like stem cells are a population of stem cells found in the bone marrow that can be mobilized and subsequently harvested from the peripheral blood of adults.
NeoStem is the first company to provide adult stem cell collection and banking services to the general adult population, and is pursuing the research and development of adult stem cell therapies, including therapies through the use of very small embryonic-like stem cells, for regenerative purposes, both in the U.S. and China, for a number of health conditions.
ImmuneRegen has previously reported on the effects of Homspera on the
differentiation of human adult stem cells, particularly into hematopoietic
stem cells that are capable of becoming blood cells and are the foundation of
the body's immune system. Very small embryonic-like stem cells are also found
in adults but may have broader applications and are
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved